Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.transproceed.2004.06.047
DC FieldValue
dc.titleAdefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplant
dc.contributor.authorWai, C.-T.
dc.contributor.authorPrabhakaran, K.
dc.contributor.authorWee, A.
dc.contributor.authorLee, Y.-M.
dc.contributor.authorDan, Y.-Y.
dc.contributor.authorSutedja, D.S.
dc.contributor.authorMak, K.
dc.contributor.authorIsaac, J.
dc.contributor.authorLee, K.-H.
dc.contributor.authorLee, H.-L.
dc.contributor.authorDa, Costa M.
dc.contributor.authorLim, S.-G.
dc.date.accessioned2011-11-30T06:34:33Z
dc.date.available2011-11-30T06:34:33Z
dc.date.issued2004
dc.identifier.citationWai, C.-T., Prabhakaran, K., Wee, A., Lee, Y.-M., Dan, Y.-Y., Sutedja, D.S., Mak, K., Isaac, J., Lee, K.-H., Lee, H.-L., Da, Costa M., Lim, S.-G. (2004). Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplant. Transplantation Proceedings 36 (8) : 2313-2314. ScholarBank@NUS Repository. https://doi.org/10.1016/j.transproceed.2004.06.047
dc.identifier.issn00411345
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/29484
dc.description.abstractComplications of hepatitis B virus (HBV) infection are among the most common indications for liver transplant in many parts of Asia. However, none of the current posttransplant hepatitis B prophylaxis strategies, namely, lamivudine, hepatitis B immunoglobulin monotherapy, or combination therapy, is ideal. Our aim was to evaluate the use of adefovir dipivoxil (ADV) as a rescue therapy for posttransplant HBV patients who developed lamivudine resistance. Twenty-two consecutive patients with HBV-related liver disease, who underwent first liver transplants from 1995 to 2002, received HBV prophylaxis with indefinite lamivudine with substitution of ADV for patients who developed drug resistance and clinical deterioration, defined as persistent elevation of transaminases or histologic deterioration. Sixteen patients (73%) were alive at their last follow-up and six (38%) had developed hepatitis B recurrence at a median of 46 (range 9 to 74) months posttransplant. Two with persistently normal transaminases and normal liver histology at 3 and 42 months postrecurrence have been continued on lamivudine. Four showed clinical deterioration and received ADV for a median of 24 months; all displayed normalization of transaminases and a 2 to 5 log drop in HBV DNA titers. Three had paired biopsies before and after substitution of ADV with two showing improvement and one stable appearance. The median serum creatinine value increased slightly from 126 to 138 μmol/L (P = 0.72). ADV is an effective rescue therapy for patients with lamivudine-resistant hepatitis B post-liver transplant. Further studies are needed to ascertain the optimal posttransplant hepatitis B prophylaxis.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.transproceed.2004.06.047
dc.sourceScopus
dc.typeConference Paper
dc.contributor.departmentSURGERY
dc.contributor.departmentPATHOLOGY
dc.contributor.departmentMEDICINE
dc.description.doi10.1016/j.transproceed.2004.06.047
dc.description.sourcetitleTransplantation Proceedings
dc.description.volume36
dc.description.issue8
dc.description.page2313-2314
dc.description.codenTRPPA
dc.identifier.isiut000225476300040
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

18
checked on Feb 25, 2020

WEB OF SCIENCETM
Citations

13
checked on Feb 18, 2020

Page view(s)

198
checked on Feb 19, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.